Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT
· Real-Time Price · USD
26.75
0.30 (1.13%)
At close: Aug 15, 2025, 2:39 PM
1.13% (1D)
| Bid | 26.54 |
| Market Cap | 19.87B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -240.75M |
| EPS (ttm) | -1.01 |
| PE Ratio (ttm) | -26.49 |
| Forward PE | -68.27 |
| Analyst | Buy |
| Ask | 29.09 |
| Volume | 1,733,794 |
| Avg. Volume (20D) | 3,890,138 |
| Open | 26.49 |
| Previous Close | 26.45 |
| Day's Range | 25.92 - 27.45 |
| 52-Week Range | 11.29 - 36.91 |
| Beta | -1.06 |
About SMMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SMMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SMMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Summit Therapeutics Inc. is scheduled to release its earnings on
Oct 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
-9.06%
Summit Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
1 month ago
+8.53%
Summit shares are trading higher after Bloomberg reported the company is in talks for a $15 billion partnership with AstraZeneca.
4 days ago · businesswire.com
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm.
